XML 48 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Schedule of Revenue by reportable segment
The following table presents the Company’s revenues by transaction type based on revenue recognition pattern for the periods presented:
Three Months Ended March 31,
20232022
Subscription revenues$393.2 $403.8 
Re-occurring revenues107.7 114.5 
Transactional and other revenues128.2 143.7 
Deferred revenues adjustment— 0.2 
Revenues, net$629.1 $662.2 
The following table summarizes revenue by reportable segment for the periods indicated:
Three Months Ended March 31,
20232022
Academia and Government$314.7 $311.8 
Intellectual Property209.1 241.8 
Life Sciences and Healthcare105.3 108.6 
Total Revenues, net$629.1 $662.2 
Schedule of Segment Reporting Information, by Segment
The following table presents segment profitability and a reconciliation to net income for the periods indicated:
Three Months Ended March 31,
20232022
Academia and Government$125.4 $104.5 
Intellectual Property94.6 117.6 
Life Sciences and Healthcare32.7 40.2 
Total Adjusted EBITDA$252.7 $262.3 
Benefit (provision) for income taxes63.6 (16.3)
Depreciation and amortization(172.6)(176.4)
Interest expense and amortization of debt discount, net(73.6)(59.5)
Mark to market (loss) gain on financial instruments(1)
(1.1)100.4 
Deferred revenues adjustment— 0.2 
Transaction related costs(2)
(1.7)(6.7)
Share-based compensation expense(41.2)(37.0)
Restructuring and impairment(3)
(9.4)(11.7)
Other(4)
26.8 14.2 
Net income$43.5 $69.5 
Dividends on preferred shares(18.8)(18.7)
Net income attributable to ordinary shares$24.7 $50.8 
(1) Reflects mark-to-market adjustments on the Private Placement Warrants under ASC 815, Derivatives and Hedging. Refer to Note 8 - Fair Value Measurements for further information.
(2) Includes costs incurred to complete business combination transactions, including acquisitions, dispositions and capital market activities and include advisory, legal, and other professional and consulting costs.
(3) Primarily reflects severance and related benefit costs related to approved restructuring programs. Refer to Note 19 - Restructuring and Impairment for further information.
(4) The current year period primarily includes the gain on legal settlement, which was partially offset by a net loss on foreign exchange re-measurement. The prior year period includes a net gain on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. Refer to Note 15 - Other Operating Income, Net and Note 17 - Commitments and Contingencies for further information.